Global Duvelisib for Relapsed CLL/SLL Market Insights, Forecast to 2030

TABLE OF CONTENTS

1 Study Coverage

• 1.1 Duvelisib for Relapsed CLL/SLL Product Introduction
• 1.2 Market by Type
  • 1.2.1 Global Duvelisib for Relapsed CLL/SLL Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
  • 1.2.2 25mg
  • 1.2.3 15mg
• 1.3 Market by Application
  • 1.3.1 Global Duvelisib for Relapsed CLL/SLL Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
  • 1.3.2 Chronic Lymphocytic Leukemia (CLL)
  • 1.3.3 Small Lymphocytic Lymphoma (SLL)
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Executive Summary

• 2.1 Global Duvelisib for Relapsed CLL/SLL Revenue Estimates and Forecasts 2019-2030
• 2.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Region
  • 2.2.1 Global Duvelisib for Relapsed CLL/SLL Revenue by Region: 2019 VS 2023 VS 2030
  • 2.2.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Region (2019-2024)
  • 2.2.3 Global Duvelisib for Relapsed CLL/SLL Revenue by Region (2025-2030)
  • 2.2.4 Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Region (2019-2030)
• 2.3 Global Duvelisib for Relapsed CLL/SLL Sales Estimates and Forecasts 2019-2030
• 2.4 Global Duvelisib for Relapsed CLL/SLL Sales by Region
  • 2.4.1 Global Duvelisib for Relapsed CLL/SLL Sales by Region: 2019 VS 2023 VS 2030
  • 2.4.2 Global Duvelisib for Relapsed CLL/SLL Sales by Region (2019-2024)
  • 2.4.3 Global Duvelisib for Relapsed CLL/SLL Sales by Region (2025-2030)
  • 2.4.4 Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Region (2019-2030)
• 2.5 US & Canada
• 2.6 Europe
• 2.7 China
• 2.8 Asia (excluding China)
• 2.9 Middle East, Africa and Latin America

3 Competition by Manufacturers

• 3.1 Global Duvelisib for Relapsed CLL/SLL Sales by Manufacturers
  • 3.1.1 Global Duvelisib for Relapsed CLL/SLL Sales by Manufacturers (2019-2024)
  • 3.1.2 Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Manufacturers (2019-2024)
  • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Duvelisib for Relapsed CLL/SLL in 2023
• 3.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Manufacturers
  • 3.2.1 Global Duvelisib for Relapsed CLL/SLL Revenue by Manufacturers (2019-2024)
  • 3.2.2 Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Manufacturers (2019-2024)
  • 3.2.3 Global Top 10 and Top 5 Companies by Duvelisib for Relapsed CLL/SLL Revenue in 2023
• 3.3 Global Key Players of Duvelisib for Relapsed CLL/SLL, Industry Ranking, 2021 VS 2022
• 3.4 Global Duvelisib for Relapsed CLL/SLL Sales Price by Manufacturers (2019-2024)
• 3.5 Analysis of Competitive Landscape
  • 3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.5.2 Global Duvelisib for Relapsed CLL/SLL Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.6 Global Key Manufacturers of Duvelisib for Relapsed CLL/SLL, Manufacturing Base Distribution and Headquarters
• 3.7 Global Key Manufacturers of Duvelisib for Relapsed CLL/SLL, Product Offered and Application
• 3.8 Global Key Manufacturers of Duvelisib for Relapsed CLL/SLL, Date of Enter into This Industry
• 3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Global Duvelisib for Relapsed CLL/SLL Sales by Type
  • 4.1.1 Global Duvelisib for Relapsed CLL/SLL Historical Sales by Type (2019-2024)
  • 4.1.2 Global Duvelisib for Relapsed CLL/SLL Forecasted Sales by Type (2025-2030)
  • 4.1.3 Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Type (2019-2030)
• 4.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Type
  • 4.2.1 Global Duvelisib for Relapsed CLL/SLL Historical Revenue by Type (2019-2024)
  • 4.2.2 Global Duvelisib for Relapsed CLL/SLL Forecasted Revenue by Type (2025-2030)
  • 4.2.3 Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Type (2019-2030)
• 4.3 Global Duvelisib for Relapsed CLL/SLL Price by Type
  • 4.3.1 Global Duvelisib for Relapsed CLL/SLL Price by Type (2019-2024)
  • 4.3.2 Global Duvelisib for Relapsed CLL/SLL Price Forecast by Type (2025-2030)

5 Market Size by Application

• 5.1 Global Duvelisib for Relapsed CLL/SLL Sales by Application
  • 5.1.1 Global Duvelisib for Relapsed CLL/SLL Historical Sales by Application (2019-2024)
  • 5.1.2 Global Duvelisib for Relapsed CLL/SLL Forecasted Sales by Application (2025-2030)
  • 5.1.3 Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Application (2019-2030)
• 5.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Application
  • 5.2.1 Global Duvelisib for Relapsed CLL/SLL Historical Revenue by Application (2019-2024)
  • 5.2.2 Global Duvelisib for Relapsed CLL/SLL Forecasted Revenue by Application (2025-2030)
  • 5.2.3 Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Application (2019-2030)
• 5.3 Global Duvelisib for Relapsed CLL/SLL Price by Application
  • 5.3.1 Global Duvelisib for Relapsed CLL/SLL Price by Application (2019-2024)
  • 5.3.2 Global Duvelisib for Relapsed CLL/SLL Price Forecast by Application (2025-2030)

6 US & Canada

• 6.1 US & Canada Duvelisib for Relapsed CLL/SLL Market Size by Type
  • 6.1.1 US & Canada Duvelisib for Relapsed CLL/SLL Sales by Type (2019-2030)
  • 6.1.2 US & Canada Duvelisib for Relapsed CLL/SLL Revenue by Type (2019-2030)
• 6.2 US & Canada Duvelisib for Relapsed CLL/SLL Market Size by Application
  • 6.2.1 US & Canada Duvelisib for Relapsed CLL/SLL Sales by Application (2019-2030)
  • 6.2.2 US & Canada Duvelisib for Relapsed CLL/SLL Revenue by Application (2019-2030)
• 6.3 US & Canada Duvelisib for Relapsed CLL/SLL Market Size by Country
  • 6.3.1 US & Canada Duvelisib for Relapsed CLL/SLL Revenue by Country: 2019 VS 2023 VS 2030
  • 6.3.2 US & Canada Duvelisib for Relapsed CLL/SLL Revenue by Country (2019-2030)
  • 6.3.3 US & Canada Duvelisib for Relapsed CLL/SLL Sales by Country (2019-2030)
  • 6.3.4 US
  • 6.3.5 Canada

7 Europe

• 7.1 Europe Duvelisib for Relapsed CLL/SLL Market Size by Type
  • 7.1.1 Europe Duvelisib for Relapsed CLL/SLL Sales by Type (2019-2030)
  • 7.1.2 Europe Duvelisib for Relapsed CLL/SLL Revenue by Type (2019-2030)
• 7.2 Europe Duvelisib for Relapsed CLL/SLL Market Size by Application
  • 7.2.1 Europe Duvelisib for Relapsed CLL/SLL Sales by Application (2019-2030)
  • 7.2.2 Europe Duvelisib for Relapsed CLL/SLL Revenue by Application (2019-2030)
• 7.3 Europe Duvelisib for Relapsed CLL/SLL Market Size by Country
  • 7.3.1 Europe Duvelisib for Relapsed CLL/SLL Revenue by Country: 2019 VS 2023 VS 2030
  • 7.3.2 Europe Duvelisib for Relapsed CLL/SLL Revenue by Country (2019-2030)
  • 7.3.3 Europe Duvelisib for Relapsed CLL/SLL Sales by Country (2019-2030)
  • 7.3.4 Germany
  • 7.3.5 France
  • 7.3.6 U.K.
  • 7.3.7 Italy
  • 7.3.8 Russia

8 China

• 8.1 China Duvelisib for Relapsed CLL/SLL Market Size by Type
  • 8.1.1 China Duvelisib for Relapsed CLL/SLL Sales by Type (2019-2030)
  • 8.1.2 China Duvelisib for Relapsed CLL/SLL Revenue by Type (2019-2030)
• 8.2 China Duvelisib for Relapsed CLL/SLL Market Size by Application
  • 8.2.1 China Duvelisib for Relapsed CLL/SLL Sales by Application (2019-2030)
  • 8.2.2 China Duvelisib for Relapsed CLL/SLL Revenue by Application (2019-2030)

9 Asia (excluding China)

• 9.1 Asia Duvelisib for Relapsed CLL/SLL Market Size by Type
  • 9.1.1 Asia Duvelisib for Relapsed CLL/SLL Sales by Type (2019-2030)
  • 9.1.2 Asia Duvelisib for Relapsed CLL/SLL Revenue by Type (2019-2030)
• 9.2 Asia Duvelisib for Relapsed CLL/SLL Market Size by Application
  • 9.2.1 Asia Duvelisib for Relapsed CLL/SLL Sales by Application (2019-2030)
  • 9.2.2 Asia Duvelisib for Relapsed CLL/SLL Revenue by Application (2019-2030)
• 9.3 Asia Duvelisib for Relapsed CLL/SLL Market Size by Region
  • 9.3.1 Asia Duvelisib for Relapsed CLL/SLL Revenue by Region: 2019 VS 2023 VS 2030
  • 9.3.2 Asia Duvelisib for Relapsed CLL/SLL Revenue by Region (2019-2030)
  • 9.3.3 Asia Duvelisib for Relapsed CLL/SLL Sales by Region (2019-2030)
  • 9.3.4 Japan
  • 9.3.5 South Korea
  • 9.3.6 China Taiwan
  • 9.3.7 Southeast Asia
  • 9.3.8 India
  • 9.3.9 Australia

10 Middle East, Africa and Latin America

• 10.1 Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Market Size by Type
  • 10.1.1 Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Sales by Type (2019-2030)
  • 10.1.2 Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Revenue by Type (2019-2030)
• 10.2 Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Market Size by Application
  • 10.2.1 Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Sales by Application (2019-2030)
  • 10.2.2 Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Revenue by Application (2019-2030)
• 10.3 Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Market Size by Country
  • 10.3.1 Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Revenue by Country: 2019 VS 2023 VS 2030
  • 10.3.2 Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Revenue by Country (2019-2030)
  • 10.3.3 Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Sales by Country (2019-2030)
  • 10.3.4 Brazil
  • 10.3.5 Mexico
  • 10.3.6 Turkey
  • 10.3.7 Israel
  • 10.3.8 GCC Countries

11 Corporate Profile

• 11.1 Secura Bio
  • 11.1.1 Secura Bio Company Information
  • 11.1.2 Secura Bio Overview
  • 11.1.3 Secura Bio Duvelisib for Relapsed CLL/SLL Sales, Price, Revenue and Gross Margin (2019-2024)
  • 11.1.4 Secura Bio Duvelisib for Relapsed CLL/SLL Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.1.5 Secura Bio Recent Developments
• 11.2 CSPC
  • 11.2.1 CSPC Company Information
  • 11.2.2 CSPC Overview
  • 11.2.3 CSPC Duvelisib for Relapsed CLL/SLL Sales, Price, Revenue and Gross Margin (2019-2024)
  • 11.2.4 CSPC Duvelisib for Relapsed CLL/SLL Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.2.5 CSPC Recent Developments

12 Industry Chain and Sales Channels Analysis

• 12.1 Duvelisib for Relapsed CLL/SLL Industry Chain Analysis
• 12.2 Duvelisib for Relapsed CLL/SLL Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 Duvelisib for Relapsed CLL/SLL Production Mode & Process
• 12.4 Duvelisib for Relapsed CLL/SLL Sales and Marketing
  • 12.4.1 Duvelisib for Relapsed CLL/SLL Sales Channels
  • 12.4.2 Duvelisib for Relapsed CLL/SLL Distributors
• 12.5 Duvelisib for Relapsed CLL/SLL Customers

13 Duvelisib for Relapsed CLL/SLL Market Dynamics

• 13.1 Duvelisib for Relapsed CLL/SLL Industry Trends
• 13.2 Duvelisib for Relapsed CLL/SLL Market Drivers
• 13.3 Duvelisib for Relapsed CLL/SLL Market Challenges
• 13.4 Duvelisib for Relapsed CLL/SLL Market Restraints

14 Key Findings in the Global Duvelisib for Relapsed CLL/SLL Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 15.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Author Details
• 15.3 Disclaimer

List of Tables

Table 1. Global Duvelisib for Relapsed CLL/SLL Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Table 2. Major Manufacturers of 25mg

Table 3. Major Manufacturers of 15mg

Table 4. Global Duvelisib for Relapsed CLL/SLL Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Table 5. Global Duvelisib for Relapsed CLL/SLL Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 6. Global Duvelisib for Relapsed CLL/SLL Revenue by Region (2019-2024) & (US$ Million)

Table 7. Global Duvelisib for Relapsed CLL/SLL Revenue by Region (2025-2030) & (US$ Million)

Table 8. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Region (2019-2024)

Table 9. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Region (2025-2030)

Table 10. Global Duvelisib for Relapsed CLL/SLL Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)

Table 11. Global Duvelisib for Relapsed CLL/SLL Sales by Region (2019-2024) & (K Units)

Table 12. Global Duvelisib for Relapsed CLL/SLL Sales by Region (2025-2030) & (K Units)

Table 13. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Region (2019-2024)

Table 14. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Region (2025-2030)

Table 15. Global Duvelisib for Relapsed CLL/SLL Sales by Manufacturers (2019-2024) & (K Units)

Table 16. Global Duvelisib for Relapsed CLL/SLL Sales Share by Manufacturers (2019-2024)

Table 17. Global Duvelisib for Relapsed CLL/SLL Revenue by Manufacturers (2019-2024) & (US$ Million)

Table 18. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Manufacturers (2019-2024)

Table 19. Global Key Players of Duvelisib for Relapsed CLL/SLL, Industry Ranking, 2021 VS 2022 VS 2023

Table 20. Duvelisib for Relapsed CLL/SLL Price by Manufacturers (2019-2024) & (US$/Unit)

Table 21. Global Duvelisib for Relapsed CLL/SLL Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 22. Global Duvelisib for Relapsed CLL/SLL by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duvelisib for Relapsed CLL/SLL as of 2023)

Table 23. Global Key Manufacturers of Duvelisib for Relapsed CLL/SLL, Manufacturing Base Distribution and Headquarters

Table 24. Global Key Manufacturers of Duvelisib for Relapsed CLL/SLL, Product Offered and Application

Table 25. Global Key Manufacturers of Duvelisib for Relapsed CLL/SLL, Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. Global Duvelisib for Relapsed CLL/SLL Sales by Type (2019-2024) & (K Units)

Table 28. Global Duvelisib for Relapsed CLL/SLL Sales by Type (2025-2030) & (K Units)

Table 29. Global Duvelisib for Relapsed CLL/SLL Sales Share by Type (2019-2024)

Table 30. Global Duvelisib for Relapsed CLL/SLL Sales Share by Type (2025-2030)

Table 31. Global Duvelisib for Relapsed CLL/SLL Revenue by Type (2019-2024) & (US$ Million)

Table 32. Global Duvelisib for Relapsed CLL/SLL Revenue by Type (2025-2030) & (US$ Million)

Table 33. Global Duvelisib for Relapsed CLL/SLL Revenue Share by Type (2019-2024)

Table 34. Global Duvelisib for Relapsed CLL/SLL Revenue Share by Type (2025-2030)

Table 35. Duvelisib for Relapsed CLL/SLL Price by Type (2019-2024) & (US$/Unit)

Table 36. Global Duvelisib for Relapsed CLL/SLL Price Forecast by Type (2025-2030) & (US$/Unit)

Table 37. Global Duvelisib for Relapsed CLL/SLL Sales by Application (2019-2024) & (K Units)

Table 38. Global Duvelisib for Relapsed CLL/SLL Sales by Application (2025-2030) & (K Units)

Table 39. Global Duvelisib for Relapsed CLL/SLL Sales Share by Application (2019-2024)

Table 40. Global Duvelisib for Relapsed CLL/SLL Sales Share by Application (2025-2030)

Table 41. Global Duvelisib for Relapsed CLL/SLL Revenue by Application (2019-2024) & (US$ Million)

Table 42. Global Duvelisib for Relapsed CLL/SLL Revenue by Application (2025-2030) & (US$ Million)

Table 43. Global Duvelisib for Relapsed CLL/SLL Revenue Share by Application (2019-2024)

Table 44. Global Duvelisib for Relapsed CLL/SLL Revenue Share by Application (2025-2030)

Table 45. Duvelisib for Relapsed CLL/SLL Price by Application (2019-2024) & (US$/Unit)

Table 46. Global Duvelisib for Relapsed CLL/SLL Price Forecast by Application (2025-2030) & (US$/Unit)

Table 47. US & Canada Duvelisib for Relapsed CLL/SLL Sales by Type (2019-2024) & (K Units)

Table 48. US & Canada Duvelisib for Relapsed CLL/SLL Sales by Type (2025-2030) & (K Units)

Table 49. US & Canada Duvelisib for Relapsed CLL/SLL Revenue by Type (2019-2024) & (US$ Million)

Table 50. US & Canada Duvelisib for Relapsed CLL/SLL Revenue by Type (2025-2030) & (US$ Million)

Table 51. US & Canada Duvelisib for Relapsed CLL/SLL Sales by Application (2019-2024) & (K Units)

Table 52. US & Canada Duvelisib for Relapsed CLL/SLL Sales by Application (2025-2030) & (K Units)

Table 53. US & Canada Duvelisib for Relapsed CLL/SLL Revenue by Application (2019-2024) & (US$ Million)

Table 54. US & Canada Duvelisib for Relapsed CLL/SLL Revenue by Application (2025-2030) & (US$ Million)

Table 55. US & Canada Duvelisib for Relapsed CLL/SLL Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 56. US & Canada Duvelisib for Relapsed CLL/SLL Revenue by Country (2019-2024) & (US$ Million)

Table 57. US & Canada Duvelisib for Relapsed CLL/SLL Revenue by Country (2025-2030) & (US$ Million)

Table 58. US & Canada Duvelisib for Relapsed CLL/SLL Sales by Country (2019-2024) & (K Units)

Table 59. US & Canada Duvelisib for Relapsed CLL/SLL Sales by Country (2025-2030) & (K Units)

Table 60. Europe Duvelisib for Relapsed CLL/SLL Sales by Type (2019-2024) & (K Units)

Table 61. Europe Duvelisib for Relapsed CLL/SLL Sales by Type (2025-2030) & (K Units)

Table 62. Europe Duvelisib for Relapsed CLL/SLL Revenue by Type (2019-2024) & (US$ Million)

Table 63. Europe Duvelisib for Relapsed CLL/SLL Revenue by Type (2025-2030) & (US$ Million)

Table 64. Europe Duvelisib for Relapsed CLL/SLL Sales by Application (2019-2024) & (K Units)

Table 65. Europe Duvelisib for Relapsed CLL/SLL Sales by Application (2025-2030) & (K Units)

Table 66. Europe Duvelisib for Relapsed CLL/SLL Revenue by Application (2019-2024) & (US$ Million)

Table 67. Europe Duvelisib for Relapsed CLL/SLL Revenue by Application (2025-2030) & (US$ Million)

Table 68. Europe Duvelisib for Relapsed CLL/SLL Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 69. Europe Duvelisib for Relapsed CLL/SLL Revenue by Country (2019-2024) & (US$ Million)

Table 70. Europe Duvelisib for Relapsed CLL/SLL Revenue by Country (2025-2030) & (US$ Million)

Table 71. Europe Duvelisib for Relapsed CLL/SLL Sales by Country (2019-2024) & (K Units)

Table 72. Europe Duvelisib for Relapsed CLL/SLL Sales by Country (2025-2030) & (K Units)

Table 73. China Duvelisib for Relapsed CLL/SLL Sales by Type (2019-2024) & (K Units)

Table 74. China Duvelisib for Relapsed CLL/SLL Sales by Type (2025-2030) & (K Units)

Table 75. China Duvelisib for Relapsed CLL/SLL Revenue by Type (2019-2024) & (US$ Million)

Table 76. China Duvelisib for Relapsed CLL/SLL Revenue by Type (2025-2030) & (US$ Million)

Table 77. China Duvelisib for Relapsed CLL/SLL Sales by Application (2019-2024) & (K Units)

Table 78. China Duvelisib for Relapsed CLL/SLL Sales by Application (2025-2030) & (K Units)

Table 79. China Duvelisib for Relapsed CLL/SLL Revenue by Application (2019-2024) & (US$ Million)

Table 80. China Duvelisib for Relapsed CLL/SLL Revenue by Application (2025-2030) & (US$ Million)

Table 81. Asia Duvelisib for Relapsed CLL/SLL Sales by Type (2019-2024) & (K Units)

Table 82. Asia Duvelisib for Relapsed CLL/SLL Sales by Type (2025-2030) & (K Units)

Table 83. Asia Duvelisib for Relapsed CLL/SLL Revenue by Type (2019-2024) & (US$ Million)

Table 84. Asia Duvelisib for Relapsed CLL/SLL Revenue by Type (2025-2030) & (US$ Million)

Table 85. Asia Duvelisib for Relapsed CLL/SLL Sales by Application (2019-2024) & (K Units)

Table 86. Asia Duvelisib for Relapsed CLL/SLL Sales by Application (2025-2030) & (K Units)

Table 87. Asia Duvelisib for Relapsed CLL/SLL Revenue by Application (2019-2024) & (US$ Million)

Table 88. Asia Duvelisib for Relapsed CLL/SLL Revenue by Application (2025-2030) & (US$ Million)

Table 89. Asia Duvelisib for Relapsed CLL/SLL Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 90. Asia Duvelisib for Relapsed CLL/SLL Revenue by Region (2019-2024) & (US$ Million)

Table 91. Asia Duvelisib for Relapsed CLL/SLL Revenue by Region (2025-2030) & (US$ Million)

Table 92. Asia Duvelisib for Relapsed CLL/SLL Sales by Region (2019-2024) & (K Units)

Table 93. Asia Duvelisib for Relapsed CLL/SLL Sales by Region (2025-2030) & (K Units)

Table 94. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Sales by Type (2019-2024) & (K Units)

Table 95. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Sales by Type (2025-2030) & (K Units)

Table 96. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Revenue by Type (2019-2024) & (US$ Million)

Table 97. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Revenue by Type (2025-2030) & (US$ Million)

Table 98. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Sales by Application (2019-2024) & (K Units)

Table 99. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Sales by Application (2025-2030) & (K Units)

Table 100. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Revenue by Application (2019-2024) & (US$ Million)

Table 101. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Revenue by Application (2025-2030) & (US$ Million)

Table 102. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 103. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Revenue by Country (2019-2024) & (US$ Million)

Table 104. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Revenue by Country (2025-2030) & (US$ Million)

Table 105. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Sales by Country (2019-2024) & (K Units)

Table 106. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Sales by Country (2025-2030) & (K Units)

Table 107. Secura Bio Company Information

Table 108. Secura Bio Description and Major Businesses

Table 109. Secura Bio Duvelisib for Relapsed CLL/SLL Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 110. Secura Bio Duvelisib for Relapsed CLL/SLL Product Model Numbers, Pictures, Descriptions and Specifications

Table 111. Secura Bio Recent Developments

Table 112. CSPC Company Information

Table 113. CSPC Description and Major Businesses

Table 114. CSPC Duvelisib for Relapsed CLL/SLL Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 115. CSPC Duvelisib for Relapsed CLL/SLL Product Model Numbers, Pictures, Descriptions and Specifications

Table 116. CSPC Recent Developments

Table 117. Key Raw Materials Lists

Table 118. Raw Materials Key Suppliers Lists

Table 119. Duvelisib for Relapsed CLL/SLL Distributors List

Table 120. Duvelisib for Relapsed CLL/SLL Customers List

Table 121. Duvelisib for Relapsed CLL/SLL Market Trends

Table 122. Duvelisib for Relapsed CLL/SLL Market Drivers

Table 123. Duvelisib for Relapsed CLL/SLL Market Challenges

Table 124. Duvelisib for Relapsed CLL/SLL Market Restraints

Table 125. Research Programs/Design for This Report

Table 126. Key Data Information from Secondary Sources

Table 127. Key Data Information from Primary Sources

List of Figures

Figure 1. Duvelisib for Relapsed CLL/SLL Product Picture

Figure 2. Global Duvelisib for Relapsed CLL/SLL Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Duvelisib for Relapsed CLL/SLL Market Share by Type: 2023 & 2030

Figure 4. 25mg Product Picture

Figure 5. 15mg Product Picture

Figure 6. Global Duvelisib for Relapsed CLL/SLL Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 7. Global Duvelisib for Relapsed CLL/SLL Market Share by Application: 2023 & 2030

Figure 8. Chronic Lymphocytic Leukemia (CLL)

Figure 9. Small Lymphocytic Lymphoma (SLL)

Figure 10. Duvelisib for Relapsed CLL/SLL Report Years Considered

Figure 11. Global Duvelisib for Relapsed CLL/SLL Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 12. Global Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 13. Global Duvelisib for Relapsed CLL/SLL Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)

Figure 14. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Region in Percentage: 2023 Versus 2030

Figure 15. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Region (2019-2030)

Figure 16. Global Duvelisib for Relapsed CLL/SLL Sales (2019-2030) & (K Units)

Figure 17. Global Duvelisib for Relapsed CLL/SLL Sales (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)

Figure 18. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Region (2019-2030)

Figure 19. US & Canada Duvelisib for Relapsed CLL/SLL Sales YoY (2019-2030) & (K Units)

Figure 20. US & Canada Duvelisib for Relapsed CLL/SLL Revenue YoY (2019-2030) & (US$ Million)

Figure 21. Europe Duvelisib for Relapsed CLL/SLL Sales YoY (2019-2030) & (K Units)

Figure 22. Europe Duvelisib for Relapsed CLL/SLL Revenue YoY (2019-2030) & (US$ Million)

Figure 23. China Duvelisib for Relapsed CLL/SLL Sales YoY (2019-2030) & (K Units)

Figure 24. China Duvelisib for Relapsed CLL/SLL Revenue YoY (2019-2030) & (US$ Million)

Figure 25. Asia (excluding China) Duvelisib for Relapsed CLL/SLL Sales YoY (2019-2030) & (K Units)

Figure 26. Asia (excluding China) Duvelisib for Relapsed CLL/SLL Revenue YoY (2019-2030) & (US$ Million)

Figure 27. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Sales YoY (2019-2030) & (K Units)

Figure 28. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Revenue YoY (2019-2030) & (US$ Million)

Figure 29. Global Duvelisib for Relapsed CLL/SLL Sales Share by Manufacturers (2023)

Figure 30. The Duvelisib for Relapsed CLL/SLL Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023

Figure 31. Global Duvelisib for Relapsed CLL/SLL Revenue Share by Manufacturers (2023)

Figure 32. The Top 5 and 10 Largest Manufacturers of Duvelisib for Relapsed CLL/SLL in the World: Market Share by Duvelisib for Relapsed CLL/SLL Revenue in 2023

Figure 33. Global Duvelisib for Relapsed CLL/SLL Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 34. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Type (2019-2030)

Figure 35. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Type (2019-2030)

Figure 36. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Application (2019-2030)

Figure 37. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Application (2019-2030)

Figure 38. US & Canada Duvelisib for Relapsed CLL/SLL Sales Market Share by Type (2019-2030)

Figure 39. US & Canada Duvelisib for Relapsed CLL/SLL Revenue Market Share by Type (2019-2030)

Figure 40. US & Canada Duvelisib for Relapsed CLL/SLL Sales Market Share by Application (2019-2030)

Figure 41. US & Canada Duvelisib for Relapsed CLL/SLL Revenue Market Share by Application (2019-2030)

Figure 42. US & Canada Duvelisib for Relapsed CLL/SLL Revenue Share by Country (2019-2030)

Figure 43. US & Canada Duvelisib for Relapsed CLL/SLL Sales Share by Country (2019-2030)

Figure 44. US Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 45. Canada Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 46. Europe Duvelisib for Relapsed CLL/SLL Sales Market Share by Type (2019-2030)

Figure 47. Europe Duvelisib for Relapsed CLL/SLL Revenue Market Share by Type (2019-2030)

Figure 48. Europe Duvelisib for Relapsed CLL/SLL Sales Market Share by Application (2019-2030)

Figure 49. Europe Duvelisib for Relapsed CLL/SLL Revenue Market Share by Application (2019-2030)

Figure 50. Europe Duvelisib for Relapsed CLL/SLL Revenue Share by Country (2019-2030)

Figure 51. Europe Duvelisib for Relapsed CLL/SLL Sales Share by Country (2019-2030)

Figure 52. Germany Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 53. France Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 54. U.K. Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 55. Italy Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 56. Russia Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 57. China Duvelisib for Relapsed CLL/SLL Sales Market Share by Type (2019-2030)

Figure 58. China Duvelisib for Relapsed CLL/SLL Revenue Market Share by Type (2019-2030)

Figure 59. China Duvelisib for Relapsed CLL/SLL Sales Market Share by Application (2019-2030)

Figure 60. China Duvelisib for Relapsed CLL/SLL Revenue Market Share by Application (2019-2030)

Figure 61. Asia Duvelisib for Relapsed CLL/SLL Sales Market Share by Type (2019-2030)

Figure 62. Asia Duvelisib for Relapsed CLL/SLL Revenue Market Share by Type (2019-2030)

Figure 63. Asia Duvelisib for Relapsed CLL/SLL Sales Market Share by Application (2019-2030)

Figure 64. Asia Duvelisib for Relapsed CLL/SLL Revenue Market Share by Application (2019-2030)

Figure 65. Asia Duvelisib for Relapsed CLL/SLL Revenue Share by Region (2019-2030)

Figure 66. Asia Duvelisib for Relapsed CLL/SLL Sales Share by Region (2019-2030)

Figure 67. Japan Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 68. South Korea Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 69. China Taiwan Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 70. Southeast Asia Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 71. India Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 72. Australia Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 73. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Sales Market Share by Type (2019-2030)

Figure 74. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Revenue Market Share by Type (2019-2030)

Figure 75. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Sales Market Share by Application (2019-2030)

Figure 76. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Revenue Market Share by Application (2019-2030)

Figure 77. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Revenue Share by Country (2019-2030)

Figure 78. Middle East, Africa and Latin America Duvelisib for Relapsed CLL/SLL Sales Share by Country (2019-2030)

Figure 79. Brazil Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 80. Mexico Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 81. Turkey Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 82. Israel Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 83. GCC Countries Duvelisib for Relapsed CLL/SLL Revenue (2019-2030) & (US$ Million)

Figure 84. Duvelisib for Relapsed CLL/SLL Value Chain

Figure 85. Duvelisib for Relapsed CLL/SLL Production Process

Figure 86. Channels of Distribution (Direct Vs Distribution)

Figure 87. Bottom-up and Top-down Approaches for This Report

Figure 88. Data Triangulation

Figure 89. Key Executives Interviewed